Udo Eichenlaub

Penzberg, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.

Journal: JAMA neurology
Published: September 19, 2022

Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19.

Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19.

Journal: Infectious diseases and therapy
Published: August 19, 2022

An accurate fully automated panel of plasma biomarkers for Alzheimer's disease.

An accurate fully automated panel of plasma biomarkers for Alzheimer's disease.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: February 27, 2022

The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort.

The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort.

Journal: Alzheimer's research & therapy
Published: November 17, 2021

Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial.

Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial.

Journal: Frontiers in immunology
Published: October 19, 2021

Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial.

Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial.

Journal: medRxiv : the preprint server for health sciences
Published: October 13, 2021

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.

Journal: JAMA neurology
Published: September 20, 2021

Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.

Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.

Journal: Neurology
Published: February 23, 2021

Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline.

Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: February 08, 2021

Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays.

Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: September 10, 2020

Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.

Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.

Journal: European journal of nuclear medicine and molecular imaging
Published: September 05, 2020

Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays.

Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays.

Journal: Scientific reports
Published: August 29, 2019
Showing 1-12 of 20

Last Updated: 09/26/2026